دورية أكاديمية
Medicinal cannabis tea contains variable doses of cannabinoids and no terpenes.
| العنوان: | Medicinal cannabis tea contains variable doses of cannabinoids and no terpenes. |
|---|---|
| المؤلفون: | Sønderskov MB; Department of Clinical Pharmacology, Aarhus University Hospital, Aarhus N, Denmark.; Department of Biomedicine, Aarhus University, Aarhus C, Denmark., Hasselstrøm JB; Department of Forensic Medicine, Aarhus University, Aarhus N, Denmark., Bahij R; Department of Green Technology, University of Southern Denmark, Odense M, Denmark., Andersen CU; Department of Clinical Pharmacology, Aarhus University Hospital, Aarhus N, Denmark.; Department of Biomedicine, Aarhus University, Aarhus C, Denmark.; Department of Forensic Medicine, Aarhus University, Aarhus N, Denmark. |
| المصدر: | Basic & clinical pharmacology & toxicology [Basic Clin Pharmacol Toxicol] 2024 Sep; Vol. 135 (3), pp. 334-344. Date of Electronic Publication: 2024 Jul 23. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Blackwell Country of Publication: England NLM ID: 101208422 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1742-7843 (Electronic) Linking ISSN: 17427835 NLM ISO Abbreviation: Basic Clin Pharmacol Toxicol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: <2005-> : Oxford : Blackwell Original Publication: Copenhagen, Denmark : Oxford, UK : Nordic Pharmacological Society Distributed by Blackwell Munksgaard, 2004- |
| مواضيع طبية MeSH: | Medical Marijuana*/administration & dosage , Medical Marijuana*/chemistry , Cannabinoids*/analysis , Cannabinoids*/administration & dosage , Cannabinoids*/chemistry , Terpenes*/analysis , Terpenes*/administration & dosage, Dronabinol/analysis ; Dronabinol/administration & dosage ; Cannabidiol/analysis ; Cannabidiol/administration & dosage ; Denmark ; Cannabis/chemistry ; Teas, Medicinal/analysis |
| مستخلص: | Tea is a recommended way of administration of prescribed cannabis plant products in Denmark. We aimed to investigate the cannabinoid and terpene doses contained in different teas. We analysed tetrahydrocannabinol (THC), tetrahydrocannabinolic acid (THCA), cannabidiol (CBD), cannabidiolic acid (CBDA), and terpene concentrations in three repeated preparations of each type of tea, and in plant material. In standard tea, concentrations of THC were [median (min-max)] 9.5 (2.3-15), 19 (13-34), and 36 (26-57) μg/mL for products with a labelled content of 6.3%, 14%, and 22% total THC (THC + THCA), respectively. The CBD concentration in tea from a product labelled with 8% total CBD (CBD + CBDA) was 7.5 (1.9-10) μg/mL. Based on this, the recommended starting amount of 0.2 L of the different teas would contain between 0.46 and 11.3 mg THC, and 0.38 to 2.0 mg CBD. Adding creamer before, but not after boiling, increased the THC and CBD concentration 2.3-4.4 and 2.1-fold, respectively. Terpenes were detected in plant material, but not in tea. The study elucidates THC and CBD doses in different teas, which may assist the clinician's choice of cannabis product. Moreover, it underscores the need for caution as administration as tea can result in exposure to different doses, even when the same cannabis product is used. (© 2024 The Author(s). Basic & Clinical Pharmacology & Toxicology published by John Wiley & Sons Ltd on behalf of Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society).) |
| References: | Russo EB. The pharmacological history of cannabis. In: Pertwee RG, ed. Handbook of cannabis. Oxford University Press; 2014. doi:10.1093/acprof:oso/9780199662685.003.0002. European Monitoring Centre for Drugs and Drug Addiction. European Drug Report 2023: Trends and Developments. Accessed 25 March, 2024. https://www.emcdda.europa.eu/publications/european-drug-report/2023_en. United Nations Office on Drugs and Crime. World Drug Report 2023. Accessed 25 March, 2024. https://www.unodc.org/unodc/en/data-and-analysis/world-drug-report-2023.html. Danish Health Authority. Udbredelse af illegale stoffer i befolkningen og blandt de unge. Narkotikasituationen i Danmark 2024. Delrapport 1. Accessed 25 March, 2024. https://sst.dk/da/fagperson/forebyggelse-og-tvaergaaende-indsatser/stoffer/overvaagning-af-narkotikasituationen. Ministry of the Interior and Health. Lov om forsøgsordning med medicinsk cannabis. LOV nr 1668 af 26/12/2017. 13.05.2021, Accessed 25 March, 2024. https://www.retsinformation.dk/eli/lta/2017/1668. Ministry of the Interior and Health. Lov om ændring af lov om forsøgsordning med medicinsk cannabis. LOV nr 2392 af 14/12/2021. Accessed 25 March, 2024. https://www.retsinformation.dk/eli/lta/2021/2392. Danish Medicines Agency. Medical cannabis. Accessed 25 March, 2024. https://laegemiddelstyrelsen.dk/da/special/medicinsk-cannabis/. Ministry of the Interior and Health. Vejledning om lægers behandling af patienter med medicinsk cannabis omfattet af forsøgsordningen. VEJ nr 9000 af 21/12/2017. Accessed 25 March, 2024. https://www.retsinformation.dk/eli/retsinfo/2018/9000. Danish Medicines Agency. Product sheet Bedrocan “CannGros”. 06.01.2023. Accessed 25 March, 2024. https://laegemiddelstyrelsen.dk/da/special/medicinsk-cannabis/forsoegsordningen-med-medicinsk-cannabis/cannabisprodukter-i-forsoegsordningen/optagelse-af-produkter-i-forsoegsordningen-for-medicinsk-cannabis/liste-over-optagne-cannabismellemprodukter/. Danish Medicines Agency. Product sheet Bediol “CannGros”. 01.06.2023. Accessed 25 March, 2024. https://laegemiddelstyrelsen.dk/da/special/medicinsk-cannabis/forsoegsordningen-med-medicinsk-cannabis/cannabisprodukter-i-forsoegsordningen/optagelse-af-produkter-i-forsoegsordningen-for-medicinsk-cannabis/liste-over-optagne-cannabismellemprodukter/. Danish Medicines Agency. Product sheet Bedica “CannGros”. 06.01.2023. Accessed 25 March, 2024. https://laegemiddelstyrelsen.dk/da/special/medicinsk-cannabis/forsoegsordningen-med-medicinsk-cannabis/cannabisprodukter-i-forsoegsordningen/optagelse-af-produkter-i-forsoegsordningen-for-medicinsk-cannabis/liste-over-optagne-cannabismellemprodukter/. Bedrocan. Cannabis products. Accessed 25 March, 2024. https://bedrocan.com/products-services/. National Academies of Sciences, Engineering, and Medicine. The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research. Vol. 2017. The National Academies Press; 2017. doi:10.17226/24625. Romano LL, Hazekamp A. Cannabis oil: chemical evaluation of an upcoming cannabis‐based medicine. Cannabinoids. 2013;1(1):1‐11. Pacifici R, Marchei E, Salvatore F, Guandalini L, Busardo FP, Pichini S. Evaluation of cannabinoids concentration and stability in standardized preparations of cannabis tea and cannabis oil by ultra‐high performance liquid chromatography tandem mass spectrometry. Clin Chem Lab Med. 2017;55(10):1555‐1563. doi:10.1515/cclm‐2016‐1060. Hazekamp A, Bastola K, Rashidi H, Bender J, Verpoorte R. Cannabis tea revisited: a systematic evaluation of the cannabinoid composition of cannabis tea. J Ethnopharmacol. 2007;113(1):85‐90. doi:10.1016/j.jep.2007.05.019. Giroud C, Menetrey A, Augsburger M, Buclin T, Sanchez‐Mazas P, Mangin P. Hemp tea versus hemp milk: behavioral, physiological effects, blood, urine, saliva and sweat cannabinoids levels following ingestion by two groups of six healthy volunteers. Probl Forens Sci. 2000;42:102‐110. Ménétrey A, Augsburger M, Favrat B, et al. Assessment of driving capability through the use of clinical and psychomotor tests in relation to blood cannabinoids levels following oral administration of 20 mg dronabinol or of a cannabis decoction made with 20 or 60 mg Delta9‐THC. J Anal Toxicol. 2005;29(5):327‐338. doi:10.1093/jat/29.5.327. Baratta F, Simiele M, Pignata I, et al. Development of standard operating protocols for the optimization of cannabis‐based formulations for medical purposes. Front Pharmacol. 2019;10:701. doi:10.3389/fphar.2019.00701. Pellesi L, Licata M, Verri P, et al. Pharmacokinetics and tolerability of oral cannabis preparations in patients with medication overuse headache (MOH)‐a pilot study. Eur J Clin Pharmacol. 2018;74(11):1427‐1436. doi:10.1007/s00228‐018‐2516‐3. Pichini S, Mannocchi G, Gottardi M, et al. Fast and sensitive UHPLC‐MS/MS analysis of cannabinoids and their acid precursors in pharmaceutical preparations of medical cannabis and their metabolites in conventional and non‐conventional biological matrices of treated individual. Talanta. 2020;209:120537. doi:10.1016/j.talanta.2019.120537. Barco S, Fucile C, Manfredini L, et al. A UHPLC‐MS/MS method for the quantification of Δ9‐tetrahydrocannabinol and cannabidiol in decoctions and in plasma samples for therapeutic monitoring of medical cannabis. Bioanalysis. 2018;10(24):2003‐2014. doi:10.4155/bio‐2018‐0184. Pérez‐Acevedo AP, Busardò FP, Pacifici R, et al. Disposition of cannabidiol metabolites in serum and urine from healthy individuals treated with pharmaceutical preparations of medical cannabis. Pharmaceuticals (Basel). 2020;13(12):459. doi:10.3390/ph13120459. Pérez‐Acevedo AP, Pacifici R, Mannocchi G, et al. Disposition of cannabinoids and their metabolites in serum, oral fluid, sweat patch and urine from healthy individuals treated with pharmaceutical preparations of medical cannabis. Phytother Res. 2021;35(3):1646‐1657. doi:10.1002/ptr.6931. Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid‐terpenoid entourage effects. Br J Pharmacol. 2011;163(7):1344‐1364. doi:10.1111/j.1476‐5381.2011.01238.x. Finlay DB, Sircombe KJ, Nimick M, Jones C, Glass M. Terpenoids from cannabis do not mediate an entourage effect by acting at cannabinoid receptors. Front Pharmacol. 2020;11:510858. doi:10.3389/fphar.2020.00359. Tveden‐Nyborg P, Bergmann TK, Jessen N, Simonsen U, Lykkesfeldt J. BCPT 2023 policy for experimental and clinical studies. Basic Clin Pharmacol Toxicol. 2023;133(4):391‐396. doi:10.1111/bcpt.13944. Ministry of Health, Welfare and Sports. Monograph Cannabis Flower. Cannabis Flos. Office of Medicinal Cannabis. Version 8.0. November 01, 2021. Accessed 25 March, 2024. https://www.cannabisbureau.nl/documenten/richtlijnen/2021/11/01/omc-monograph-cannabis-flower-version-8.0-november-01-2021. Ministry of the Interior and Health. Bekendtgørelse om Danske Lægemiddelstandarder 2023.2. BEK nr 659 af 30/05/2023. Accessed 25 March, 2024. https://www.retsinformation.dk/eli/lta/2023/659. Danish medicines Agency. Product sheet, Bedrocan “CannGros” 27.01.2020. No longer available. 2020. https://laegemiddelstyrelsen.dk/da/special/medicinsk-cannabis/virksomheder/forsoegsordningen/produkter-i-forsoegsordningen/liste-over-optagne-cannabisprodukter/. Danish Medicines Agency. Product sheet, Bediol “CannGros” 27.01.2020. No longer available. 2020. https://laegemiddelstyrelsen.dk/da/special/medicinsk-cannabis/virksomheder/forsoegsordningen/produkter-i-forsoegsordningen/liste-over-optagne-cannabisprodukter/. Danish Medicines Agency. Product sheet, Bedica “Canngros” 27.01.2020. No longer available. 2020. https://laegemiddelstyrelsen.dk/da/special/medicinsk-cannabis/virksomheder/forsoegsordningen/produkter-i-forsoegsordningen/liste-over-optagne-cannabisprodukter/. Sorensen LK, Hasselstrom JB. Sensitive determination of cannabinoids in whole blood by LC‐MS‐MS after rapid removal of phospholipids by filtration. J Anal Toxicol. 2017;41(5):382‐391. doi:10.1093/jat/bkx030. Molnar A, Lewis J, Fu S. Recovery of spiked Δ9‐tetrahydrocannabinol in oral fluid from polypropylene containers. Forensic Sci Int. 2013;227(1–3):69‐73. doi:10.1016/j.forsciint.2012.11.006. Anderson LL, Low IK, Banister SD, McGregor IS, Arnold JC. Pharmacokinetics of phytocannabinoid acids and anticonvulsant effect of cannabidiolic acid in a mouse model of Dravet syndrome. J Nat Prod. 2019;82(11):3047‐3055. doi:10.1021/acs.jnatprod.9b00600. Danish Medicines Agency. Sativex, mundhulespray, opløsning. 22.11.2023. Summary of product characteristics. Accessed 6 May, 2024. https://www.produktresume.dk/. Kim J, Choi P, Park YT, Kim T, Ham J, Kim JC. The cannabinoids, CBDA and THCA, rescue memory deficits and reduce amyloid‐beta and tau pathology in an Alzheimer's disease‐like mouse model. Int J Mol Sci. 2023;24(7):6827. doi:10.3390/ijms24076827. Carmona‐Hidalgo B, González‐Mariscal I, García‐Martín A, et al. Δ9‐Tetrahydrocannabinolic acid markedly alleviates liver fibrosis and inflammation in mice. Phytomedicine. 2021;81:153426. doi:10.1016/j.phymed.2020.153426. |
| معلومات مُعتمدة: | EMN-2018-01114 Medicine Fund of the Danish Regions; 19-L-0087 The A.P. Moller Foundation; 19-B-0082 The Health Foundation; Aarhus University; A2339 Health Research Foundation of Central Denmark Region |
| فهرسة مساهمة: | Keywords: cannabinoids; cannabis tea; drug formulation; medicinal cannabis; terpenes |
| المشرفين على المادة: | 0 (Medical Marijuana) 0 (Cannabinoids) 0 (Terpenes) 7J8897W37S (Dronabinol) 19GBJ60SN5 (Cannabidiol) FJX8O3OJCD (cannabidiolic acid) |
| تواريخ الأحداث: | Date Created: 20240723 Date Completed: 20240815 Latest Revision: 20240815 |
| رمز التحديث: | 20240816 |
| DOI: | 10.1111/bcpt.14056 |
| PMID: | 39044312 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1742-7843 |
|---|---|
| DOI: | 10.1111/bcpt.14056 |